Merck KGaA (MKKGY)
| Market Cap | 56.91B |
| Revenue (ttm) | 24.78B |
| Net Income (ttm) | 3.06B |
| Shares Out | n/a |
| EPS (ttm) | 7.04 |
| PE Ratio | 18.59 |
| Forward PE | 14.12 |
| Dividend | 0.34 (1.20%) |
| Ex-Dividend Date | Apr 29, 2025 |
| Volume | 5,513 |
| Average Volume | 67,475 |
| Open | 27.42 |
| Previous Close | 28.78 |
| Day's Range | 26.36 - 27.62 |
| 52-Week Range | 24.32 - 31.00 |
| Beta | 0.73 |
| RSI | 32.53 |
| Earnings Date | Mar 5, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography... [Read more]
Full Company ProfileFinancial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial numbers in EUR Financial StatementsNews
DAX Up Slightly; Deutsche Post, Merck KGaA Down On Weak Updates
BRUSSELS (dpa-AFX) - German stocks are turning in a mixed performance in cautious trading Thursday morning as investors continue to closely follow the updates about the Middle East conflict. Oil's...
Merck KGaA 2025 Q4 - Results - Earnings Call Presentation
2026-03-05. The following slide deck was published by Merck KGaA in conjunction with their 2025 Q4 earnings call.
Merck KGaA (MKGAF) Reports Stable 2025 Earnings and Dividend
Merck KGaA (MKGAF) Reports Stable 2025 Earnings and Dividend
Merck KGaA Non-GAAP EPS of €8.34, revenue of €21.1B; introduces FY26 outlook
Merck KGaA FY25 Profit Down, Sees Weak Results In FY26
(RTTNews) - German science and technology major Merck KGaA (MKKGY) reported Thursday lower profit in fiscal 2025, amid slightly lower net sales. Further, the company maintained dividend, and issued fi...
Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
Merck KGaA sees earnings decline of up to 4%
Germany's Merck KGaA said on Thursday it expects 2026 adjusted operating profit to slip by up to 4%, excluding currency effects.
ClearBridge International Value Strategy adds RHHBY and MKGAF; exits GRRMF, AKESF, and HKMPF
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson
Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.
Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'
Sanofi SA (NASDAQ: SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson . As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially worth over $3 billio...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related Disorders
LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson's and related disorders.
Merck KGaA (MKKGY) Q3 2025 Earnings Call Transcript
Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Florian Schraeder - Head of Investor Relations Belén Garijo López - Chair of Executive Board & CEO Hel...
Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
Merck KGaA's sales grew 5.2%, driven by demand for pharma-production products, rare diseases treatments and semiconductor materials in its electronics unit.
Merck KGaA's Q3 profit rises, beats market view
Merck KGaA reported on Thursday a slight gain in quarterly operating earnings that beat market expectations, benefiting from legislative changes in South America and the sale of a priority review vouc...
Merck KGaA: An AI-Resistant Pharma Play
Merck KGaA (MKGAF) is deeply undervalued, offering a compelling entry point with strong fundamentals and resilience to AI disruption. MKGAF's diversified segments—life science, healthcare (biologics),...
Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.
President Donald Trump on Thursday announced a deal with EMD Serono, a subsidiary of German drugmaker Merck KGaA, that aims to cut the out-of-pocket costs for in vitro fertilization, with the move com...
Trump announces efforts to expand access to IVF drugs
President Donald Trump announced two new efforts to expand availability of in vitro fertilization, the first concrete step from the Trump administration on the expensive, decades-old procedure. It inc...
Trump Announces Deal With Germany's Merck on IVF Costs
President Donald Trump announces a deal with Germany's Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs. He speaks during a a press confere...
Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
Germany's Merck tweaks mid-term healthcare unit guidance
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Chinese police investigating app fraud case, says German drugmaker Merck KGaA
Police in China are investigating an app fraud case, said German healthcare firm Merck KGaA , amid growing concerns over entities claiming affiliation with major corporations.
Merck and Siemens Deepen Strategic Partnership to Accelerate AI and Data-Driven Drug Discovery and Development
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strateg...